Literature DB >> 17850588

Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression.

P Zhang1, F Gao, Q Wang, X Wang, F Zhu, C Ma, W Sun, L Zhang.   

Abstract

The engagement of the 4-1BB (CD137) co-stimulatory pathway promotes the activation and proliferation of conventional CD4(+) T and CD8(+) T cells, but the role of 4-1BB co-stimulation in CD4(+) CD25(+) regulatory T cells (Treg) is less clear. In particular, whether 4-1BB stimulation affects the expression of Foxp3, a master gene for Treg, is unknown. This study demonstrates that co-stimulation of 4-1BB engaged by an agonistic antibody promotes the proliferation of Treg in a dependent manner of low-concentration interleukin-2 in vitro. The 4-1BB-expanded Treg maintain Foxp3 expression and their ability to suppress conventional CD4(+) T cells and their feature to produce no interleukin-2. However, the 4-1BB-expanded Treg produce increased levels of interferon-gamma, whose significance is unknown. Thus, 4-1BB co-stimulation plays a role in the expansion of functional CD4(+) CD25(+) Treg cells without adversely affecting their suppressive activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850588     DOI: 10.1111/j.1365-3083.2007.01994.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  28 in total

1.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

Review 2.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Authors:  Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 3.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

4.  A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.

Authors:  Joseph M Ryan; Payal Mittal; Antoine Menoret; Julia Svedova; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Cancer Immunol Immunother       Date:  2018-01-11       Impact factor: 6.968

5.  Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.

Authors:  Crystal Morales Del Valle; Joseph R Maxwell; Maria M Xu; Antoine Menoret; Payal Mittal; Naomi Tsurutani; Adam J Adler; Anthony T Vella
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

6.  Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling.

Authors:  Julia M Martínez Gómez; J Ludovic Croxford; Kim Pin Yeo; Véronique Angeli; Herbert Schwarz; Stephan Gasser
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

Review 7.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

8.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

Review 9.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

10.  Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.

Authors:  Payal Mittal; Marie-Clare St Rose; Xi Wang; Joseph M Ryan; Jeffrey S Wasser; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2015-11-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.